Sirolimus, the first mTOR inhibitor

MeSH terms

• Angiogenesis Inhibitors / pharmacology
• Angiogenesis Inhibitors / therapeutic use
• Animals
• Apoptosis / drug effects
• Atherosclerosis / prevention & control
• Bone Marrow Diseases / chemically induced
• Cell Division / drug effects
• Clinical Trials as Topic
• Cyclosporine / adverse effects
• Graft Rejection / prevention & control
• Graft vs Host Disease / drug therapy
• Graft vs Host Disease / prevention & control
• Humans
• Immunosuppressive Agents / adverse effects
• Immunosuppressive Agents / pharmacokinetics
• Immunosuppressive Agents / pharmacology*
• Immunosuppressive Agents / therapeutic use
• Kidney Diseases / chemically induced
• Kidney Transplantation / immunology
• Lymphocyte Subsets / cytology
• Lymphocyte Subsets / drug effects
• Mice
• Multicenter Studies as Topic
• Muscle, Smooth, Vascular / drug effects
• Neoplasms / drug therapy
• Neoplasms / etiology
• Neoplasms / prevention & control
• Postoperative Complications / drug therapy
• Postoperative Complications / etiology
• Postoperative Complications / prevention & control
• Sirolimus / adverse effects
• Sirolimus / pharmacokinetics
• Sirolimus / pharmacology*
• Sirolimus / therapeutic use
• TOR Serine-Threonine Kinases / antagonists & inhibitors*
• Wound Healing / drug effects